BACKGROUND: The aim of the study was to assess the 7-year-follow-up (7FU) after Autologous Matrix Induced Chondrogenesis plus Peripheral Blood Concentrate (AMIC+PBC) in chondral defects at the first metatarsophalangeal joint (MTP1). MATERIAL AND METHODS: In a prospective consecutive non-controlled clinical follow-up study, all patients with chondral lesion at MTP1 that were treated with AMIC+PBC from April 1, 2009 from July 17, 2016 to May 21, 2017 were included. Size and location of the chondral lesions, the Visual-Analogue-Scale Foot and Ankle (VAS FA) and the European Foot and Ankle Society Score (EFAS Score) before treatment and at 5FU were analysed and compared with previous 2- and 5-year-follow-up (2FU/5FU). Peripheral Blood Concentrate (PBC) was used to impregnate a collagen I/III matrix (Chondro-Gide, Wolhusen, Switzerland) that was fixed into the chondral lesion with fibrin glue. RESULTS: One hundred and ninety-eight patients with 228 chondral defects were included. In 21 % of patients no deformities in the forefoot were registered. The average degree of osteoarthritis was 2.2. The chondral defect size was 1.0 cm CONCLUSIONS: In conclusion, AMIC+PBC as treatment for chondral defects at MTP1 as part of joint preserving surgery led to improved and high validated outcome scores at 7FU. The lack of significant differences between 2-year (2FU), 5-year (5FU), and 7-year (7FU) outcomes suggests plateaued benefits.